60-80% (oral) 60-80% (oral; not significantly affected by food)'"`UNIQ--ref-00000843-QINU`"' 64-90% (oral; not affected by food)'"`UNIQ--ref-00000079-QINU`"' 65-75% (oral)'"`UNIQ--ref-0000013F-QINU`"' 70-75% (oral)'"`UNIQ--ref-000007ED-QINU`"' 70-80% (oral)'"`UNIQ--ref-000002A4-QINU`"' 75-90% (oral; minimally affected by food)'"`UNIQ--ref-000001A2-QINU`"' 80-90% oral 90% (oral; food delays but does not reduce absorption)'"`UNIQ--ref-000004F3-QINU`"' <0.1% systemic absorption (PEG 3350 is too large to absorb intact) <1% (oral; further reduced by food, calcium, iron, antacids; hence the strict fasting/upright dosing rules)'"`UNIQ--ref-000006C4-QINU`"' <1% oral (extensive first-pass via CYP3A4); ~30% inhaled lung deposition'"`UNIQ--ref-000001DE-QINU`"' <3% systemic absorption (the basis of the safety and mechanism)'"`UNIQ--ref-00000F5E-QINU`"' <5% (extensive hepatic first-pass; food enhances absorption of IR, hence the evening-meal dosing)'"`UNIQ--ref-00000808-QINU`"' <5% (extensive hepatic first-pass; statin pharmacology is hepatocellular, not systemic)'"`UNIQ--ref-0000017B-QINU`"' <5% systemic absorption (this is the safety basis)'"`UNIQ--ref-00000DC3-QINU`"' >90% (oral)'"`UNIQ--ref-0000001C-QINU`"' >90% (oral; food slows absorption and reduces peaks, hence the post-meal dosing rule)'"`UNIQ--ref-000001BD-QINU`"' >90% (oral; not affected by food or gastric pH — a major practical advantage over itraconazole)'"`UNIQ--ref-00000A48-QINU`"' >90% (oral; not significantly affected by food)'"`UNIQ--ref-00001120-QINU`"' Absolute bioavailability not precisely characterized; food modestly increases exposure Acid-labile; not effective orally (oral form available outside US as penicillin G salts but penicillin V is preferred for oral use)'"`UNIQ--ref-0000141A-QINU`"' Adequate (food-dependent, must take with fatty meal) Adequate oral bioavailability Adequate oral bioavailability with extended-release formulation Buprenorphine ~30% SL; naloxone <10% SL (intentional, inactive sublingually, matters only if injected) Butalbital well-absorbed; aspirin 50-75%; caffeine ~100%'"`UNIQ--ref-000015B8-QINU`"' Butalbital well-absorbed; caffeine ~100%; acetaminophen 85-98%'"`UNIQ--ref-000015A0-QINU`"' Carbonate ~30-40% (best with food and acid); citrate ~24% (absorbable without acid; preferred in achlorhydria, PPI use, post-bariatric) Codeine ~60% (oral); acetaminophen 85-98%'"`UNIQ--ref-00001518-QINU`"' Essentially zero systemic absorption from oral or topical routes — the topical-action-only profile is the basis of its safety'"`UNIQ--ref-00000D18-QINU`"' High (oral) High (oral); not significantly affected by food'"`UNIQ--ref-00000397-QINU`"' High (oral)'"`UNIQ--ref-00000FB5-QINU`"' High (oral)'"`UNIQ--ref-00001051-QINU`"' High (oral)'"`UNIQ--ref-00001165-QINU`"' High (oral)'"`UNIQ--ref-000012A0-QINU`"' High (oral; absorption not affected by food)'"`UNIQ--ref-00000825-QINU`"' High (oral; food enhances)'"`UNIQ--ref-00001039-QINU`"' High (oral; food prolongs absorption modestly)'"`UNIQ--ref-00000622-QINU`"' High (oral; not affected by food, but typically given with the morning meal)'"`UNIQ--ref-0000027D-QINU`"' High (oral; not significantly affected by food)'"`UNIQ--ref-00000B65-QINU`"' High with fat-containing meal; reduced in malabsorption Highly formulation-dependent; the goal is colonic delivery with minimal systemic exposure'"`UNIQ--ref-00000BBF-QINU`"' Highly route-dependent: SL bypasses first-pass; oral has extensive first-pass (used only for chronic ER preparations); transdermal predictable'"`UNIQ--ref-00000C10-QINU`"' Highly salt-dependent: citrate ~25-30%; oxide ~4% (limited and causes osmotic diarrhea); chloride ~12% Highly variable due to saturable first-pass metabolism'"`UNIQ--ref-0000002C-QINU`"' IM/SC ~100%; oral negligible (extensive first-pass and gut metabolism — hence the no-oral route)'"`UNIQ--ref-00000E53-QINU`"' IV/IM ~100%; inhaled: minimal systemic; oral: negligible (not used orally for systemic infection)'"`UNIQ--ref-000010B4-QINU`"' Improved with food'"`UNIQ--ref-00000052-QINU`"' Increased substantially via CYP2D6 inhibition'"`UNIQ--ref-00001584-QINU`"' Increased with food (varies by formulation; the micronized and nanocrystal forms are less food-dependent)'"`UNIQ--ref-000004AE-QINU`"' Inhaled lung deposition with minimal systemic absorption (the basis of the favorable safety profile vs systemic antimuscarinics)'"`UNIQ--ref-00000F7C-QINU`"' Inhaled lung deposition ~20%; systemic absorption from lung ~33%; oral component negligible'"`UNIQ--ref-000009C1-QINU`"' Intranasal ~40% systemic; ophthalmic minimal'"`UNIQ--ref-000013B7-QINU`"' Intranasal: <1% systemic; inhaled lung deposition with extensive first-pass clearance'"`UNIQ--ref-00000F9D-QINU`"' Limited but adequate; take with food Local (intramuscular) Local action; minimal systemic effect Low systemic absorption (enteric coating delivers drug to colon)'"`UNIQ--ref-0000106C-QINU`"' Mononitrate ~100% (no first-pass; the principal advantage over dinitrate); dinitrate ~20%'"`UNIQ--ref-00001462-QINU`"' Naltrexone ~5% (oral, extensive first-pass to 6β-naltrexol); bupropion ER ~87%'"`UNIQ--ref-00001569-QINU`"' Negligible (not absorbed)'"`UNIQ--ref-00000058-QINU`"' Negligible systemic absorption'"`UNIQ--ref-0000119D-QINU`"' Not characterized; oral dosing once daily Not formally characterized for the combination Not formally characterized in humans. Not formally established Not formally established (high SC) Not formally established; oral once-daily adequate Not well characterized Not well characterized'"`UNIQ--ref-00000019-QINU`"' Olanzapine 60% (oral); fluoxetine high (oral)'"`UNIQ--ref-0000154E-QINU`"' Oral bioavailability of psilocin from administered psilocybin approximately 50% Oral bioavailability suitable for daily dosing Oral non-undecanoate has essentially zero bioavailability (hepatic first-pass) Oral ~1-3% via passive diffusion at high doses (independent of intrinsic factor); IM/SC ~100% Oral ~5% (extensive first-pass to estrone and conjugates); transdermal bypasses first-pass, giving more physiologic estradiol:estrone ratio'"`UNIQ--ref-000003BB-QINU`"' Oral ~70%; depot IM provides sustained release over weeks'"`UNIQ--ref-0000101B-QINU`"' Oral ~90%; depot IM essentially 100% over the dosing interval'"`UNIQ--ref-00000F21-QINU`"' Oral: very low (extensive first-pass); micronization improves uptake somewhat. Vaginal: high local effect with lower systemic levels (first-uterine-pass concentration)'"`UNIQ--ref-00000727-QINU`"' Oxycodone 60-87%; aspirin 50-75%'"`UNIQ--ref-000014FB-QINU`"' Rapid absorption; absolute bioavailability not formally established Reasonable (not formally established as a percentage) SC ~47%–65%'"`UNIQ--ref-0000005A-QINU`"' SC ~55%'"`UNIQ--ref-0000018B-QINU`"' SC ~65%–75%<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> SC ~80%<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> SC ~89%<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> · Oral ~0.4–1% (SNAC-enhanced)'"`UNIQ--ref-00000254-QINU`"' Sandimmune: highly variable (~30%); Neoral microemulsion: ~50%, less variable; '''Sandimmune and Neoral are NOT bioequivalent and not interchangeable''''"`UNIQ--ref-00000A92-QINU`"' Substantially improved with high-fat meal; take with food'"`UNIQ--ref-000013D2-QINU`"' Sumatriptan ~15% (oral; substantial first-pass); naproxen ~95%'"`UNIQ--ref-000015D2-QINU`"' Tablet ~100% relative to oral solution; extensive first-pass metabolism Topical with limited but measurable systemic absorption'"`UNIQ--ref-00001219-QINU`"' Topical with measurable systemic absorption (small CA inhibition observed clinically with chronic use)'"`UNIQ--ref-00000B0B-QINU`"' Topical with minimal systemic absorption'"`UNIQ--ref-000011DA-QINU`"' Topical with minimal systemic absorption'"`UNIQ--ref-0000123A-QINU`"' Topical with minimal systemic absorption'"`UNIQ--ref-00001288-QINU`"' Topical with variable systemic absorption depending on body site, occlusion, and skin integrity; HPA-axis suppression is documented even with brief courses to large areas'"`UNIQ--ref-0000079F-QINU`"' Topical/intranasal: high local, low systemic; intra-articular: local depot then systemic absorption'"`UNIQ--ref-00000667-QINU`"' Topical/oral local action with minimal systemic absorption'"`UNIQ--ref-00001399-QINU`"' Topical: local effect on enamel; systemic supplementation has high oral bioavailability with skeletal accumulation Topical: minimal systemic absorption (oral systemic 5-FU not used due to poor and variable absorption)'"`UNIQ--ref-000011BF-QINU`"' Topical: minimal systemic absorption with normal skin; oral: variable, induced metabolism with repeated dosing'"`UNIQ--ref-00000BA4-QINU`"' Topical: minimal systemic; oral: pH-dependent, requires gastric acid'"`UNIQ--ref-00000889-QINU`"' Topical: minimal systemic; troche: ~3% systemic'"`UNIQ--ref-00000F46-QINU`"' Topical; clinically meaningful systemic absorption can produce systemic α2 effects (somnolence, hypotension), especially in children'"`UNIQ--ref-000010D2-QINU`"' Topical; minimal systemic absorption'"`UNIQ--ref-00000418-QINU`"' Topical; minimal systemic absorption'"`UNIQ--ref-00000A03-QINU`"' Topical; minimal systemic absorption'"`UNIQ--ref-00000DA2-QINU`"' Tramadol ~75% (oral); acetaminophen 85-98%'"`UNIQ--ref-00001531-QINU`"' Variable (oral; rapidly conjugated to active glucuronide; food does not affect)'"`UNIQ--ref-00000451-QINU`"' Variable; reduced by food, calcium, iron, PPIs'"`UNIQ--ref-00000037-QINU`"' ~0.3% (oral; extensive first-pass via CYP3A4 and P-glycoprotein-mediated efflux at the intestinal and blood-brain barriers limit systemic and CNS exposure at therapeutic doses)'"`UNIQ--ref-00000FD3-QINU`"' ~10% inhaled reaches systemic circulation; ~50% PO'"`UNIQ--ref-0000009A-QINU`"' ~100% (oral); highly (~90%) protein-bound, with non-linear binding above therapeutic levels (free fraction matters clinically in hypoalbuminemia)'"`UNIQ--ref-0000097D-QINU`"' ~100% (oral)'"`UNIQ--ref-0000001B-QINU`"' ~100% (oral)'"`UNIQ--ref-00000020-QINU`"' ~100% (oral)'"`UNIQ--ref-00000027-QINU`"' ~100% (oral)'"`UNIQ--ref-00000706-QINU`"' ~100% (oral, but oral use is limited to continuation from parenteral)'"`UNIQ--ref-00000021-QINU`"' ~100% (oral; absorption complete)'"`UNIQ--ref-0000126F-QINU`"' ~100% (oral; food delays absorption, hence pre-meal dosing for IR)'"`UNIQ--ref-000002DA-QINU`"' ~100% (oral; near-complete absorption)'"`UNIQ--ref-00000018-QINU`"' ~100% (oral; not significantly affected by food)'"`UNIQ--ref-00000493-QINU`"' ~100% both components ~100% from subcutaneous depot (by definition of the route) ~12% (extensive metabolizers); ~96% (poor metabolizers) ~14% (extensive hepatic first-pass)'"`UNIQ--ref-0000001C-QINU`"' ~14% (oral; substantial first-pass); ~97% (subcutaneous); ~17% (nasal)'"`UNIQ--ref-00000016-QINU`"' ~15% (extensive hepatic first-pass) ~15% (oral; highly variable due to extensive and variable first-pass metabolism)'"`UNIQ--ref-00000022-QINU`"' ~17% (oral; food slightly reduces absorption)'"`UNIQ--ref-000003D6-QINU`"' ~20% (oral; hydrophilic, minimal CYP metabolism, mostly excreted unchanged in bile)'"`UNIQ--ref-000000FD-QINU`"' ~20% (oral; valacyclovir prodrug raises this to ~55%)'"`UNIQ--ref-00000910-QINU`"' ~20-35% (oral; extensive first-pass via CYP3A4 with R/S enantiomer differences)'"`UNIQ--ref-00000A6C-QINU`"' ~22–25% ~25% (extensive hepatic first-pass) ~25% (high first-pass) ~25% (oral)'"`UNIQ--ref-00000019-QINU`"' ~25% (oral, with extensive first-pass)'"`UNIQ--ref-00000023-QINU`"' ~25% (oral; extensive first-pass)'"`UNIQ--ref-0000001B-QINU`"' ~25% (oral; food does not affect absorption)'"`UNIQ--ref-0000005A-QINU`"' ~25% (oral; food reduces absorption ~40%)'"`UNIQ--ref-000004CE-QINU`"' ~25-35% (extensive first-pass), increased by food which slows absorption and reduces orthostatic risk'"`UNIQ--ref-0000001C-QINU`"' ~25-40% (oral; extensive first-pass)'"`UNIQ--ref-00000021-QINU`"' ~25-50% (oral; substantial first-pass via NAT2 acetylation, phenotype-dependent)'"`UNIQ--ref-00000688-QINU`"' ~26% (oral; prodrug hydrolyzed by intestinal esterases to active olmesartan; not affected by food)'"`UNIQ--ref-0000056D-QINU`"' ~28% (oral; food slows but does not reduce absorption)'"`UNIQ--ref-00000C33-QINU`"' ~30% (high first-pass) ~30% (oral)'"`UNIQ--ref-00000021-QINU`"' ~30% (oral)'"`UNIQ--ref-0000117D-QINU`"' ~30-65% (oral; acid-labile, hence enteric-coated formulations; food affects absorption variably)'"`UNIQ--ref-00000D3F-QINU`"' ~33% ~33% (extensive first-pass via CYP2C9 and CYP3A4)'"`UNIQ--ref-000000BD-QINU`"' ~33% (oral; fruit juices including grapefruit, orange, and apple reduce absorption substantially via OATP1A2 inhibition — distinctive interaction not seen with most other H1s)'"`UNIQ--ref-00000CCD-QINU`"' ~33-55% (IR); reduced by food'"`UNIQ--ref-0000001B-QINU`"' ~35% (oral, extensive first-pass; not used orally for systemic effect); ~100% (IV)'"`UNIQ--ref-00000021-QINU`"' ~36% (oral)'"`UNIQ--ref-00000C93-QINU`"' ~37% (oral, as axetil prodrug; food modestly improves absorption)'"`UNIQ--ref-00000FFA-QINU`"' ~37% (oral; food does not affect)'"`UNIQ--ref-00000A23-QINU`"' ~37% (oral; food reduces absorption modestly)'"`UNIQ--ref-000003FD-QINU`"' ~38% (oral; non-acidic prodrug improves GI tolerability over many other NSAIDs)'"`UNIQ--ref-000011FA-QINU`"' ~4% (extensive first-pass metabolism)'"`UNIQ--ref-0000001E-QINU`"' ~40% ~40% (oral); food and formulation substantially alter the absorption profile'"`UNIQ--ref-0000001E-QINU`"' ~40% (oral; extensive first-pass via CYP3A4)'"`UNIQ--ref-00000643-QINU`"' ~40% (oral; food does not significantly affect)'"`UNIQ--ref-00000EB3-QINU`"' ~40-60% (oral, with significant first-pass)'"`UNIQ--ref-00000027-QINU`"' ~44% ~45% (oral)'"`UNIQ--ref-00000C73-QINU`"' ~45% (oral; substantially higher than sumatriptan's ~14%)'"`UNIQ--ref-00000013-QINU`"' ~45%'"`UNIQ--ref-00000027-QINU`"' ~48% intranasal ~5% intranasal ~5-20% (extensive first-pass), highly variable between individuals'"`UNIQ--ref-00000024-QINU`"' ~50% ~50% (highly variable) ~50% (oral); systemic absorption from ophthalmic application is clinically meaningful via nasolacrimal drainage'"`UNIQ--ref-0000001C-QINU`"' ~50% (oral)'"`UNIQ--ref-00000027-QINU`"' ~50% (oral)'"`UNIQ--ref-000002C5-QINU`"' ~50% (oral; highly variable)'"`UNIQ--ref-00000CB4-QINU`"' ~50% (oral; highly variable, 10-100%, hence the standard 1:2 IV-to-PO conversion)'"`UNIQ--ref-00000223-QINU`"' ~50% (oral; not significantly affected by food)'"`UNIQ--ref-000001FC-QINU`"' ~50% (oral; reduced by buffering and enteric coating but onset clinically similar)'"`UNIQ--ref-00000028-QINU`"' ~50% (oral; substantial first-pass)'"`UNIQ--ref-00000024-QINU`"' ~50% (variable, CYP2D6-dependent for analgesic effect). ~50% IR (extensive first-pass via CYP3A4); ER products release-rate-limited'"`UNIQ--ref-0000074E-QINU`"' ~50-60% (oral; food enhances) ~50-60% (oral; substantial first-pass metabolism)'"`UNIQ--ref-0000002A-QINU`"' ~53% (oral)'"`UNIQ--ref-00000024-QINU`"' ~55% (oral)'"`UNIQ--ref-00000016-QINU`"' ~55% bioavailability of acyclovir after valacyclovir oral (vs ~20% from oral acyclovir directly)'"`UNIQ--ref-000005D7-QINU`"' ~58% (extended-release); ~80% (immediate-release)'"`UNIQ--ref-00000021-QINU`"' ~6% IR oral (substantial first-pass to active N-desethyl metabolite, which contributes most of the antimuscarinic adverse effects); transdermal bypasses first-pass and is better tolerated'"`UNIQ--ref-000006E2-QINU`"' ~6-13% inhaled lung deposition; ~10% oral (Entocort EC; extensive first-pass via CYP3A4 — this is the basis of the favorable hepatic-targeted local-effect profile in IBD)'"`UNIQ--ref-000009A6-QINU`"' ~60% ~60% (oral); ~100% (IM)'"`UNIQ--ref-00000027-QINU`"' ~60% (oral)'"`UNIQ--ref-00000379-QINU`"' ~60% (oral)'"`UNIQ--ref-00000D5A-QINU`"' ~60% (oral; food does not affect absorption)'"`UNIQ--ref-00000B85-QINU`"' ~60% (oral; phenoxymethyl modification makes it acid-stable, unlike penicillin G which is destroyed by gastric acid)'"`UNIQ--ref-00000E77-QINU`"' ~60% (oral; substantially increased with high-fat meal)'"`UNIQ--ref-00001093-QINU`"' ~60% from subcutaneous depot (reduced by reversible albumin binding via the myristic acid side chain that also extends duration)'"`UNIQ--ref-00001375-QINU`"' ~60-87% (oral; high and more consistent than codeine or hydrocodone, making efficacy less CYP2D6-genotype-dependent)'"`UNIQ--ref-0000001E-QINU`"' ~60-87% oxycodone (high and predictable, less CYP-genotype-dependent than codeine or hydrocodone); 85-98% acetaminophen'"`UNIQ--ref-000014E3-QINU`"' ~60–70% (oral) ~62% ~63% (oral)'"`UNIQ--ref-00000532-QINU`"' ~63% (oral; extensive first-pass)'"`UNIQ--ref-00000015-QINU`"' ~64% (oral)'"`UNIQ--ref-00000016-QINU`"' ~64% (oral; not significantly affected by food)'"`UNIQ--ref-0000015F-QINU`"' ~64% from SC depot'"`UNIQ--ref-00001104-QINU`"' ~64-90% (oral; increases at higher doses and with multi-day dosing)'"`UNIQ--ref-000008E9-QINU`"' ~65% (oral)'"`UNIQ--ref-0000001E-QINU`"' ~65% (oral)'"`UNIQ--ref-00000784-QINU`"' ~65% (oral)'"`UNIQ--ref-00000AB1-QINU`"' ~65% (oral)'"`UNIQ--ref-000013F6-QINU`"' ~67% (oral)'"`UNIQ--ref-00000B26-QINU`"' ~70% (oral)'"`UNIQ--ref-0000001B-QINU`"' ~70% (oral)'"`UNIQ--ref-00000022-QINU`"' ~70% (oral)'"`UNIQ--ref-000008C5-QINU`"' ~70% (oral; bioavailability and absorption are improved with food)'"`UNIQ--ref-00000355-QINU`"' ~70% (oral; reduced by divalent cations — antacids, iron, calcium, dairy)'"`UNIQ--ref-00000939-QINU`"' ~70-85% (oral)'"`UNIQ--ref-00000027-QINU`"' ~70-90% at typical doses; saturable at high doses (>500 mg) ~72% (with food); much lower fasting (~36%) ~72% from SC depot'"`UNIQ--ref-00001480-QINU`"' ~72% oral; ~85% smoked'"`UNIQ--ref-00000066-QINU`"' ~75% ~75% (IR, rises with multi-dose administration due to saturable first-pass)'"`UNIQ--ref-0000001E-QINU`"' ~75% (oral, as the active carboxylate after hepatic esterase activation)'"`UNIQ--ref-00000E95-QINU`"' ~75% (oral; absorption improved with fat-containing meal) ~75% (oral; fat-soluble, absorption requires intact biliary/lipid digestion)'"`UNIQ--ref-00000331-QINU`"' ~75-85% (oral); ~60% (transdermal at steady state)'"`UNIQ--ref-00000027-QINU`"' ~75–90% (oral) ~77% (oral; not affected by food or antacids)'"`UNIQ--ref-0000011E-QINU`"' ~78% (oral; high-fat meal modestly reduces but is not clinically significant)'"`UNIQ--ref-00000553-QINU`"' ~80% (oral)'"`UNIQ--ref-0000001B-QINU`"' ~80% (oral)'"`UNIQ--ref-0000001E-QINU`"' ~80% (oral)'"`UNIQ--ref-00000029-QINU`"' ~80% (oral)'"`UNIQ--ref-00000310-QINU`"' ~80% (oral)'"`UNIQ--ref-00000BEC-QINU`"' ~80% (oral)'"`UNIQ--ref-00000E2C-QINU`"' ~80% (oral; predictable absorption — a substantive practical advantage over furosemide whose oral absorption is 10-100% variable)'"`UNIQ--ref-00000B47-QINU`"' ~80% (oral; reduced by significant first-pass)'"`UNIQ--ref-00000EFA-QINU`"' ~80-100% (oral)'"`UNIQ--ref-00000027-QINU`"' ~80-100% with food at 15-20 mg doses (10 mg dose: ~80% without food); '''must be taken with food''' at therapeutic doses'"`UNIQ--ref-00000514-QINU`"' ~80-95% (oral; more reliable than furosemide, comparable to torsemide)'"`UNIQ--ref-00000DE4-QINU`"' ~80-99% (oral)'"`UNIQ--ref-00000868-QINU`"' ~82% ~82% SC ~85-90% (oral; not significantly affected by food)'"`UNIQ--ref-00000955-QINU`"' ~85-98% (oral)'"`UNIQ--ref-000006A6-QINU`"' ~87% (oral)'"`UNIQ--ref-00000024-QINU`"' ~87% (oral)'"`UNIQ--ref-00000766-QINU`"' ~89% (oral)'"`UNIQ--ref-00000021-QINU`"' ~90% (low first-pass) ~90% (oral)'"`UNIQ--ref-00000018-QINU`"' ~90% (oral)'"`UNIQ--ref-00000024-QINU`"' ~90% (oral)'"`UNIQ--ref-00000027-QINU`"' ~90% (oral)'"`UNIQ--ref-00000DFF-QINU`"' ~90% (oral)'"`UNIQ--ref-00001140-QINU`"' ~90% (oral)'"`UNIQ--ref-00001443-QINU`"' ~90% (oral, low first-pass)'"`UNIQ--ref-0000001C-QINU`"' ~90% (oral; food increases absorption)'"`UNIQ--ref-000008A4-QINU`"' ~90% (oral; not affected by food but reduced by divalent cations)'"`UNIQ--ref-00000D83-QINU`"' ~93% (oral); ~90% (rectal)'"`UNIQ--ref-00000027-QINU`"' ~93% (oral)'"`UNIQ--ref-00000ED4-QINU`"' ~95% (oral)'"`UNIQ--ref-0000001F-QINU`"' ~95% (oral)'"`UNIQ--ref-0000002A-QINU`"' ~95% (oral)'"`UNIQ--ref-0000149E-QINU`"' ~95% (oral)'"`UNIQ--ref-000014C4-QINU`"' ~95% (oral; reduced by dairy, antacids, iron via divalent-cation chelation, though less than for tetracycline itself)'"`UNIQ--ref-0000047E-QINU`"' ~96% (oral)'"`UNIQ--ref-00000AD2-QINU`"' ~96% after red blood cell hydrolytic cleavage releases dextroamphetamine'"`UNIQ--ref-00000018-QINU`"' ~98% (oral)'"`UNIQ--ref-00000026-QINU`"' ~99% (caffeine) ~99% (oral)'"`UNIQ--ref-0000002A-QINU`"' ~99% (oral; matched 1:1 IV-to-PO conversion)'"`UNIQ--ref-00000CF6-QINU`"' ≥90% (linear pharmacokinetics, distinguishing it favorably from gabapentin's saturable LAT-1 absorption)'"`UNIQ--ref-00000027-QINU`"'
:
12 hours 
generic:
duration: (Click arrow to add another value)